
|Videos|November 11, 2016
Current Progress and Future With Glembatumumab Vedotin in TNBC
Author(s)Linda T. Vehdat, MD, PhD
Linda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the current progress being made with glembatumumab vedotin in triple-negative breast cancer (TNBC) and what the future holds for this agent.

















